Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.67 |
| ▸ | AKR1B1 | P15121 | 9/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509653 | 0.88 | PTGDR2 (0.79) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6509675 | 0.87 | PTGDR2 (0.77) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6512615 | 0.86 | PTGDR2 (0.85) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6519926 | 0.84 | PTGDR2 (0.68) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6511175 | 0.82 | PTGDR2 (0.76) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6519008 | 0.81 | PTGDR2 (0.84) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6527321 | 0.81 | PTGDR2 (0.87) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL4903988 | 0.81 | PTGDR2 (1.00) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6512642 | 0.79 | PTGDR2 (0.84) | PTGDR2AKR1B1SLC6A4CYP2C9 | |
| SCHEMBL6519941 | 0.77 | PTGDR2 (0.80) | PTGDR2AKR1B1SLC6A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005121141-A1 | PYRROLOPYRIDINE DERIVATIVES AND USE THEREOF FOR TREATING DISEASES MEDIATED BY PROSTAGLANDIN D2 (PGD2) | OXAGEN LIMITED (GB) | 2005-12-22 | — | — | WO | claimed |
| WO-2005121141-A1 | PYRROLOPYRIDINE DERIVATIVES AND USE THEREOF FOR TREATING DISEASES MEDIATED BY PROSTAGLANDIN D2 (PGD2) | OXAGEN LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |